European Expansion Clonmel Healthcare has expanded facilities to Ireland, Northern Europe and Europe with a newly constructed warehouse facility, indicating growing manufacturing and distribution capacity to support current and new partners across the region.

Parkinson's Focus The APO-go POD launch of apomorphine hydrochloride places Clonmel in the specialty therapy space, offering potential to collaborate with neurology clinics and Parkinson's care channels for distribution and patient access.

Irish Generics Leader Clonmel is positioned as the number one generic supplier by value and volume in the Irish market, highlighting strong local demand and opportunities to extend the portfolio into additional Irish and cross-border channels.

STADA Portfolio Leverage As part of the STADA Group with a global footprint, Clonmel can potentially leverage broader distribution, contracting and co-development opportunities for generics, specialty medicines and consumer health products.

Leadership Signals A new Managing Director appointed in May 2025 alongside ongoing product launches and capacity expansion signals a strategic growth plan, creating openings for executive engagement on partnerships, sourcing and supply agreements.